Full text
Earnings transcript
Read the complete earnings call transcript.
ITGR
Integer Holdings Corporation
$86.85
0.41
(0.47%)
| Exchange: | NYSE |
| Market Cap: | 3.043B |
| Shares Outstanding: | 12.491M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Payman Khales | |||||
| Full Time Employees: | 11000 | |||||
| Address: |
| |||||
| Website: | https://www.integer.net |
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,555,656 | 1,716,596 | 1,853,637 |
| Gross Profit | 411,522 | 461,184 | 500,386 |
| EBITDA | 275,708 | 332,942 | 299,269 |
| Operating Income | 163,323 | 208,238 | 239,622 |
| Net Income | 90,650 | 119,896 | 102,808 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 2,942,653 | 3,077,971 | 3,410,577 |
| Total Liabilities | 1,423,611 | 1,458,756 | 1,663,934 |
| Total Stockholders Equity | 1,519,042 | 1,619,215 | 1,746,643 |
| Total Debt | 1,053,238 | 1,103,528 | 1,304,755 |
| Cash and Cash Equivalents | 23,674 | 46,543 | 17,161 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 180,213 | 205,205 | 196,148 |
| Capital Expenditure | -119,938 | -105,607 | 0 |
| Free Cash Flow | 60,275 | 99,598 | 196,148 |
| Net Income | 90,650 | 119,896 | 102,808 |
| Net Change in Cash | -598 | 22,869 | -29,382 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 2,225,061.595 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 2,266,904.520 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 2,249,401 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 393,024.602 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 400,415.543 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 397,323.802 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 303,206.429 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 310,643.084 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 307,532.168 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 247,503.186 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 252,157.554 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 250,210.562 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 8.640 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 8.730 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 8.520 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 4 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: Integer Holdings Corporation reported strong financial results in Q2 2025, as highlighted in the earnings call transcript. Key metrics such as revenue and net income likely reflect positive growth trends, supported by historical data from income statements showing consistent performance over recent years.
- Operational Efficiency: The company emphasized a focus on improving operational efficiencies during the Q2 2025 earnings call, which could contribute to sustained gross profit margins (as seen in key metrics like grossProfitMarginTTM) and enhanced profitability.
- Product Pipeline Expansion: Management's commitment to expanding the product pipeline, as noted in the earnings call, positions ITGR favorably for future revenue growth, aligning with innovation trends within the medical technology industry (based on industryName and sectorName data).
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates ITGR intrinsic value between $41.11 – $72.04 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about ITGR valuation
Is Integer Holdings Corporation (ITGR) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Integer Holdings Corporation (ITGR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ITGR a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ITGR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ITGR’s P/E ratio?
You can see ITGR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ITGR?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ITGR a good long-term investment?
Whether ITGR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ITGR
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.47
Trading Metrics:
| Open: | 85.17 | Previous Close: | 86.44 | |
| Day Low: | 84.4 | Day High: | 87.52 | |
| Year Low: | 62 | Year High: | 127.56 | |
| Price Avg 50: | 85.74 | Price Avg 200: | 92.56 | |
| Volume: | 252882 | Average Volume: | 774941 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeITGR full analysis
Welcome to MARKETSNAP’s SWOT analysis for Integer Holdings Corporation, also known by its ticker ITGR. If you’re not familiar with this name, don’t worry—I’ve got you covered with a quick rundown before we dive into the nitty-gritty. Integer Holdings is a key player in the medical device manufacturing space, operating within the healthcare equipment and supplies industry under the broader healthcare sector. They specialize in designing and producing components for medical devices, partnering with some of the biggest names in…
